ExpreS2ion Biotech Holding AB (publ) (EXPRS2) Q1 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Welcome to today's event where we have the pleasure to present Expression Biotech. As you can see here on the front page the Q1 report is of course the reason for today and the main topic for today and of course the pipeline news. So it was through today's presentation I answer questions in the end. We are joined by CEO Ben Fransen and CFO Keith Alexander. As always, there's a box down below where you can ask questions. If you do it in Danish, I will try and translate to the best of my ability. We have a firm stop at 10.30, so I will catch as many questions as possible. But we have a firm stop at 10.30. So I will not take any more time and leave the word over to you, Bent. Thank you, Michael. And good morning, everyone. And welcome to Expressions Q126 webcast. I'm Ben Fransen, CEO of Expression Biotech, and with me today is our CFO, Keith Alexander. I'll first walk through the key development across our pipeline and platform activities during the first quarter, and particularly progress in our HER2 breast cancer immunotherapy project, as well as our grant-funded infectious diseases programs before Keith takes over and goes through the financial results. And of course, we'll take questions in the end. We'll try to go through this quickly to allow for that. During Q1 2026, we continue to advance both our clinical program and broader platform activities. Across the quarter, we reported progress in financing activities, ESOB C001 clinical development, platform validation through partner programs, manufacturing advancement in the Nipah virus project, and continued strengthening of our IP position. Most notably, we reported encouraging preliminary immunogenicity observations from the ongoing phase one trial of ES2B-C001. Subsequently, we reported drug-specific antibody res...